Shares of Arcturus Therapeutics Holdings fell after the company’s loss widened more than expected in the second quarter.
The stock was down 7.9% to $29.32 in after-hours trading. Shares have risen 88% so far this year as of Monday’s close.
The San Diego-based RNA medicines company reported a second-quarter loss of $52.55 million, or $1.98 a share, compared with $21.56 million, or 82 cents a share, a year earlier. Analysts polled by FactSet expected a loss of $1.34 a share.
The company’s revenue sank to $10.5 million from $27.1 million a year ago. Arcturus said the decline was largely attributable to the termination of an agreement with Vinbiocare and lower revenue from the company’s agreement with the Israeli Ministry of Health.